These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16255370)

  • 1. [The Medical Products Agency didn't "choose" Artrox].
    Rastad JA
    Lakartidningen; 2005 Oct 3-9; 102(40):2886. PubMed ID: 16255370
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucosamine in osteoarthritis.
    Cumming A
    Lancet; 1999 Nov; 354(9190):1640-1; author reply 1641-2. PubMed ID: 10560694
    [No Abstract]   [Full Text] [Related]  

  • 3. [It's only afterwards the Medical Products Agency can scrutinize advertisements].
    Forslund L; Gerdén B
    Lakartidningen; 2008 Aug 27-Sep 2; 105(35):2348. PubMed ID: 18833633
    [No Abstract]   [Full Text] [Related]  

  • 4. [The Medical Products Agency: the tampon Ellen should be regulated as a pharmaceutical product].
    Bruse GW
    Lakartidningen; 2009 Aug 5-18; 106(32-33):1995. PubMed ID: 19764383
    [No Abstract]   [Full Text] [Related]  

  • 5. Glucosamine & chondroitin use questioned in mild cases. Drug combo benefits moderate-to-severe knee osteoarthritis, but not so with lesser cases.
    Health News; 2006 Mar; 12(3):5-6. PubMed ID: 16535766
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucosamine for pain in osteoarthritis: why do trial results differ?
    Vlad SC; LaValley MP; McAlindon TE; Felson DT
    Arthritis Rheum; 2007 Jul; 56(7):2267-77. PubMed ID: 17599746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current role of glucosamine in the treatment of osteoarthritis.
    Reginster JY; Bruyere O; Neuprez A
    Rheumatology (Oxford); 2007 May; 46(5):731-5. PubMed ID: 17401134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucosamine in the treatment of osteoarthritis.
    Clayton P
    Tidsskr Nor Laegeforen; 2008 Mar; 128(6):714; author reply 714. PubMed ID: 18337857
    [No Abstract]   [Full Text] [Related]  

  • 9. Information from your family doctor. Glucosamine and osteoarthritis.
    American Academy of Family Physicians
    Am Fam Physician; 2008 Aug; 78(4):481. PubMed ID: 18756655
    [No Abstract]   [Full Text] [Related]  

  • 10. [Which factors should influence the choice of drugs?].
    Lakartidningen; 1975 Oct; 72(40):3828-34. PubMed ID: 1177612
    [No Abstract]   [Full Text] [Related]  

  • 11. Current concepts in the therapeutic management of osteoarthritis with glucosamine.
    Reginster JY; Bruyere O; Fraikin G; Henrotin Y
    Bull Hosp Jt Dis; 2005; 63(1-2):31-6. PubMed ID: 16536216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription of glucosamine for osteoarthritis: does it work and is it safe?
    Wollheim FA
    Nat Clin Pract Rheumatol; 2007 Jul; 3(7):364-5. PubMed ID: 17534290
    [No Abstract]   [Full Text] [Related]  

  • 13. FPIN's clinical inquiries. Glucosamine and chondroitin for osteoarthritis.
    Fox BA; Schmitz ED; Wallace R
    Am Fam Physician; 2006 Apr; 73(7):1245-6. PubMed ID: 16623213
    [No Abstract]   [Full Text] [Related]  

  • 14. [Factory inspection--a method of drug control].
    Bill E
    Lakartidningen; 1968 Jun; 65():Suppl 2:97-100. PubMed ID: 5712533
    [No Abstract]   [Full Text] [Related]  

  • 15. [The licence drug policy of the Medical Drug Agency. Permitted use in special needs].
    Rastad JA; Klintberg K; Von Bahr C
    Lakartidningen; 1996 Nov; 93(47):4309-10. PubMed ID: 8984304
    [No Abstract]   [Full Text] [Related]  

  • 16. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest.
    Reginster JY
    Arthritis Rheum; 2007 Jul; 56(7):2105-10. PubMed ID: 17599727
    [No Abstract]   [Full Text] [Related]  

  • 17. [Sweden can contribute to safer drug assessment].
    Strandberg K
    Lakartidningen; 2006 Jun 8-13; 103(23):1853-5. PubMed ID: 16838598
    [No Abstract]   [Full Text] [Related]  

  • 18. [Glucosamine and conflict of interest].
    Storm-Henningsen P
    Tidsskr Nor Laegeforen; 2007 Nov; 127(22):2971; author reply 2971. PubMed ID: 18026251
    [No Abstract]   [Full Text] [Related]  

  • 19. [The Medical Product Agency sharpens its control. What is the consequence of bad trials?].
    Naeser SW; Nordlund S
    Lakartidningen; 1993 Dec; 90(51-52):4651-2. PubMed ID: 8264311
    [No Abstract]   [Full Text] [Related]  

  • 20. Marginal efficacy of glucosamine: comment on the article by VLAD et al and the editorial by Reginster.
    Greenwald RA
    Arthritis Rheum; 2008 Jan; 58(1):332; author reply 333-4. PubMed ID: 18163480
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.